Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
30-Year Treasury Yield Falls to 5.524% -- Data Talk

30-Year Treasury Yield Falls to 5.524% -- Data Talk

Dow JonesDow Jones2026/10/14 19:26

The 30-year yield declined 0.038 percentage point to 5.524% today. The price rose 17/32 to 94 6/32.

--Yield is down for four consecutive trading days

--Yield is down 0.137 percentage point over the last four trading days

--Largest four-day yield decline since Tuesday, May 26, 2026

--Longest streak of falling yields since Thursday, June 18, 2026 when the yield fell for four straight trading days

--Yield is down five of the past six trading days

--Lowest yield since Friday, Sept. 25, 2026

--Yield is off 0.140 percentage point from its 52-week high of 5.664% hit Monday, Oct. 5, 2026

--Yield is up 0.985 percentage point from its 52-week low of 4.539% hit Wednesday, Oct. 22, 2025

--Yield is up 0.885 percentage point from 52 weeks ago

--Yield is up 0.892 percentage point from its 2026 closing low of 4.632% hit Friday, Feb. 27, 2026

--Month-to-date the yield is down 0.115 percentage point

--Year-to-date the yield is up 0.694 percentage point

Data based on 3 p.m. ET values

Source: Tradeweb FTSE U.S. Treasury Closing Prices

(END) Dow Jones Newswires

October 14, 2026 15:26 ET (19:26 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss